CLAIMS

1. A method for treatment of neurological or immunological disorders in a patient comprising the step of stimulating secretion of pancreatic juices in said patient.

2. The method of claim 2 wherein the step of stimulating secretion of pancreatic juices comprises the step of administering to said patient an effective amount of secretin.

3. The method of claim 2 wherein said effective amount of secretin is administered by infusion.

4. The method of claim 3 wherein administering said effective amount of secretin by infusion includes the step of intravenously infusing secretin in an amount of about 2 clinical units (CU) per kilogram (kg) of body weight.

5. The method of claim 2 wherein said effective amount of secretin is administered transdermally.

6. The method of claim 5 wherein administering said effective amount of secretin transdermally includes the steps of:

applying a transdermal carrier substance to a portion of the skin of said patient; and

applying crystalline secretin in said effective amount onto said transdermal carrier substance.

7. The method of claim 6 wherein said transdermal carrier substance includes dimethyl sulfoxide (DMSO).

8. The method of claim 6 wherein said effective amount of secretin includes between 5 and 20 clinical units (CU) of crystalline secretin per dose.

9. The method of claim 6 wherein said transdermal carrier substance is selected from the group consisting of a gel and a lotion.

10. The method of claim 5 wherein administering secretin transdermally includes administering said effective amount of secretin with a patch to be applied to a portion of the skin of said patient.

11. The method of claim 5 wherein administering secretin transdermally includes administering said effective amount of secretin using acoustic waves causing said secretin to permeate a skin surface of said patient.

12. The method of claim 2 wherein said effective amount of secretin is administered orally.

13. The method of claim 12 wherein said effective amount of secretin is administered orally using an oral carrier selected from the group consisting of a tablet, capsule or lozenge.

14. The method of claim 2 wherein said effective amount of secretin is administered using a suppository.

15. The method of claim 2 wherein said effective amount of secretin is administered by inhalation.

16. The method of claim 2 wherein said neurological disorders include autistic spectrum disorders.

17. The method of claim 2 wherein said effective amount of secretin includes an amount of secretin sufficient to increase serotonin levels in the brain of said patient.

18. The method of claim 1 wherein stimulating secretion of said pancreatic juices increases at least one neuropeptide hormone select from the group consisting of serotonin, dopamine and CCK levels in said patient.

19. The method of claim 1 wherein the step of stimulating secretion of pancreatic juices includes the step of causing secretion of an effective amount of secretin in said patient.

20. The method of claim 19 wherein the step of causing secretion of an effective amount of secretin in said patient includes stimulating the duodenum of said patient to produces secretin.

21. A composition for treatment of neurological or immunological disorders in a patient comprising an effective amount of secretin and a physiologically acceptable carrier.

22. The composition of claim 21 wherein said physiologically acceptable carrier includes a transdermal carrier substance.

23. The composition of claim 22 wherein said transdermal carrier substance includes dimethyl sulfoxide (DMSO).

24. The composition of claim 23 wherein said effective amount of secretin includes about 15 clinical units (CU) of crystalline secretin per dose.

25. The composition of claim 21 wherein said physiologically acceptable carrier includes sodium chloride for dissolving said effective amount of secretin.

26. The composition of claim 25 wherein said effective amount of secretin includes about 2 clinical units (CU) per kilogram (kg) of body weight of said patient per dose.

27. The composition of claim 21 wherein said physiologically acceptable carrier includes an oral carrier.

28. The composition of claim 21 wherein said physiologically acceptable carrier includes an inhalable carrier.

29. The composition of claim 21 wherein said composition is for the treatment of autism.

30. A method for the treatment of autism comprising the step of administering to said patient an effective amount of secretin.

31. The method of claim 30 wherein said effective amount of secretin is administered by infusion.

32. The method of claim 31 wherein administering said effective amount of secretin by infusion includes the step of intravenously transfusing secretin in an amount of about 2 clinical units (CU) per kilogram (kg) of body weight per dose.

33. The method of claim 30 wherein said effective amount of secretin is administered transdermally.

34. The method of claim 33 wherein administering said effective amount of secretin transdermally includes the steps of:

applying a transdermal carrier substance to a portion of the skin of said patient; and

applying crystalline secretin in said effective amount onto said transdermal carrier substance.

35. The method of claim 34 wherein said transdermal carrier substance includes dimethyl sulfoxide (DMSO).

36. The method of claim 35 wherein said effective amount of secretin includes about 15 clinical units (CU) of crystalline secretin per dose.